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the other hand, a positive FDG-PET examination does not necessar-
ily mean that the lymph node is invaded and hence tissue diagnosis is 
necessary to conﬁrm or deny disease. Recent observations also indicate 
that larger lymph nodes on CT with no FDG-uptake may require tissue 
sampling because these nodes would have a larger probability for N2 
disease. This suggests that for adequate staging of the mediastinum 
both anatomic and metabolic information are necessary. This informa-
tion is also offered by integrated PET-CT scanners. When tissue needs 
to be obtained, mediastinoscopy is usually performed. However, newer 
minimally invasive biopsy techniques such as transbronchial needle as-
piration performed during bronchoscopy, during endoscopic ultrasound 
(EUS-FNA) or during endobronchial ultrasound (EBUS-FNA) may 
replace the more invasive mediastinoscopy in some speciﬁc situations. 
Comparing CT with these minimally invasive techniques is probably 
not totally appropriate but several studies have shown that CT results 
were inferior to those of EUS-FNA.
Assessment of distant metastases
It is generally agreed that an investigation for distant metastases 
should be started when the patient has signs and symptoms that might 
be caused by metastatic disease and when the patient has a primary 
tumour that requires extensive surgery. In these situations CT and 
MR imaging can play an important role. However, the approach to 
detection of occult metastases remains controversial, both in terms of 
when to search and of the optimal technique that should be used. In 
most institutions the thoracic CT is routinely extended to include the 
upper part of the abdomen allowing staging of the adrenals and liver. 
However, the adrenal masses that are often found in patients staged 
for NSCLC very often correspond with benign adenomas. In addition, 
extensive CT scanning only rarely detects silent metastases, except 
in patients with extensive tumour. So a possible approach could be to 
restrict imaging studies for the detection of extra-thoracic metasta-
ses to patients with clinical symptoms suggesting metastases and to 
patients with advanced lung cancer. The introduction of FDG-PET and 
integrated PET-CT may, however, change this approach. Many reports 
suggest that FDG-PET is, except for brain metastases, more sensitive 
than CT in the diagnosis of extra-thoracic metastases. In addition, since 
the whole body is automatically examined when a FDG-PET of the 
chest is performed, this technique could detect occult metastases, which 
may change patientís management. However, the clinical signiﬁcance 
of a single focal abnormality on FDG-PET may be unclear, especially 
when no morphologic alterations are seen on CT images. In this situa-
tion integrated PET-CT could be valuable since exact correlation of the 
FDG accumulation becomes possible. Finally, it should be emphasized 
that patients with abnormal study results should not be excluded from 
potentially curative surgery without tissue conﬁrmation, except when 
the clinical and radiological evidence is overwhelming.
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Lung cancer staging using the International System for Staging Lung 
Cancer describes the extent of NSCLC in terms of the size, location, 
and extent of the primary tumor (T descriptor), the presence and loca-
tion of lymph node involvement (N descriptor), and the presence or 
absence of distant metastatic disease (M descriptor). Radiologic evalua-
tion and interpretation are important components of the clinical staging 
evaluation and can greatly inﬂuence whether the patient is treated with 
surgical resection, radiation therapy, chemotherapy, or a combination of 
these modalities. Common imaging modalities for staging lung cancer 
are chest radiographs, CT, MRI, PET and fused PET/CT. The most 
common radiologic examination in the lung cancer patient is chest 
CT because of its ability to provide anatomical information regard-
ing the primary tumor as well as evaluate the extent of mediastinal 
and extrathoracic disease. In addition, whole body positron-emission 
tomography (PET) using 18-ﬂuorodeoxyglucose (FDG), especially 
fused PET/CT has become an important correlative imaging study for 
staging lung cancer. The application of PET/CT and its interpretation 
in the clinical staging of mediastinal lymph nodes is the focus of this 
discussion. 
CT is useful for anatomic identiﬁcation of mediastinal lymph nodes, 
but is limited in evaluating metastatic involvement of the lymph nodes. 
Meta-analyses review of staging NSCLC with CT indicates the limita-
tions of CT for staging the mediastinum. In one review by Dales et al 
of 42 studies, there was a combined sensitivity of 83%, a speciﬁcity 
of 82%, and an accuracy of 80%. Dwamena et al reviewed 29 studies 
and reported a combined sensitivity of 60%, speciﬁcity of 77%, and 
accuracy of 75%. This limitation is primarily because CT only shows 
the size, shape and location of mediastinal lymph nodes, not the bio-
logic activity. PET imaging with FDG, which demonstrates metabolic 
activity, has been shown to be more accurate (reported accuracy, 81% 
- 96%) than CT and MRI in the detection of nodal disease. PET is also 
useful in differentiating hyperplastic nodes from metastatic nodes and 
for detecting metastasis within normal size nodes. In the meta-analysis 
of nodal staging by Dwamena, the sensitivity of PET was 79% and 
speciﬁcity was 91% compared to 60% and 77% for CT (41). Fused 
PET/CT imaging provides registration of FDG metabolic activity with 
anatomic detail of CT and has been reported to be more accurate than 
PET or CT alone in staging patients with NSCLC. Antoch et al reported 
that the accuracy for detecting metastatic mediastinal lymph nodes was 
63% for CT alone, 89% for PET alone, and 93% for PET/CT, while 
the sensitivity and speciﬁcity was 89% and 94% for PET/CT, 89% and 
89% PET, and 70% and 59% for CT. The improvement in mediastinal 
staging with PET/CT continues to be supported in the literature; a re-
cent report by Kim et al in Cancer, 2007, indicates PET/CT mediastinal 
nodal; staging in 674 patients to have a sensitivity of 61%, speciﬁcity 
of 96% and accuracy of 86%. 
Assessment of mediastinal adenopathy for radiation oncologist is also 
important because involved nodes are included in their treatment plan. 
CT done for radiotherapy treatment planning is usually done without 
contrast, and many of these patients will not undergo mediastinoscopy; 
fused imaging for metabolic tumor localization and an experienced 
radiologist interpretation of metastatic nodal disease are important. 
PET/CT is reported to alter the radiation therapy treatment plan in more 
than 50% of patients with NSCLC when compared to CT alone. Fused 
imaging can also be used to differentiate suspected metastatic disease 
from benign lesions and to help differentiate recurrent tumor from 
radiation changes. 
